Jordyn Sava is an editor for Targeted Oncology.
Recommended Phase 2 Dose of Tebentafusp Shows Promise in Metastatic Uveal Melanoma
June 17th 2022A manageable side-effect profile, signal of efficacy, and 36% increase in the recommended phase 2 dose (RP2D) was seen with a step-up dosing regimen of tebentafusp in patients with metastatic uveal melanoma.
Investigation of Novel CAR T Product, MB-106, in Various R/R B-Cell Malignancies
June 16th 2022In an interview with Targeted Oncology, Mazyar Shadman, MD, MPH, discussed his research of MB-106 as treatment for patients with relapsed or refractory B-non-Hodgkin lymphoma and chronic lymphocytic leukemia.
New Agent Investigated for Patients With RET Fusions Given a Prior RET Inhibitor
June 14th 2022In an interview with Targeted Oncology, Nathan Pennell, MD, PhD, discussed the basis of the LOXO-NGR-21001 trial evaluating LOXO-260 in patients who have previously received a prior selective RET inhibitor.
European Commission Approves Mosunetuzumab for Patients with R/R Follicular Lymphoma
June 12th 2022The European Commission has granted a conditional marketing authorization to mosunetuzumab for the treatment of adult patients with relapsed or refractory follicular lymphoma who have previously received at least 2 prior systemic therapies